Serotonin norepinephrine reuptake inhibitors in anxiety disorders: a comprehensive review of their clinical efficacy
Serotonin norepinephrine reuptake inhibitors in anxiety disorders: a comprehensive review of their clinical efficacy
Anxiety disorders are common psychiatric conditions that typically require long-term treatment. This review summarizes current knowledge of the pharmacological treatment of anxiety disorders with serotonin norepinephrine reuptake inhibitors (SNRIs) with specific emphasis on the findings of recent randomized clinical trials and relevant neurobiological investigations. It is now well established that gabaergic, noradrenergic and serotonergic systems play a critical role in the pathophysiology of anxiety disorders, abnormalities in these systems being related to structural and functional alterations in specific brain areas such as the amygdala, prefrontal cortex, locus coeruleus and hippocampus, as repeatedly shown by neuroimaging studies. SNRIs selectively inhibit norepinephrine and serotonin reuptake and have shown to be efficacious and generally well tolerated treatments in patients with anxiety disorders, with some potential clinical advantages over selective serotonin reuptake inhibitors (SSRIs), which are considered by many to represent first-line pharmacological treatments in patients with anxiety disorders. Anxiety disorders are characterized by a typically chronic course, high rates of comorbidity and frequent partial response to standard treatments, and the increasing use of SNRIs reflects currently unmet clinical need, in terms of overall response, remission rates and treatment tolerability.
serotonin norepinephrine reuptake inhibitors (SNRIs), anxiety disorders (ADs), selective serotonin reuptake inhibitors (SSRIs)
17-29
Dell'Osso, Bernardo
92b13aa3-d1bb-46d8-83cd-ed220cf450b5
Buoli, Massimiliano
60c3b145-3335-4e44-97df-705b561af888
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Altamura, A. Carlo
4cb41390-7275-49ec-9bef-5e517e671df4
January 2010
Dell'Osso, Bernardo
92b13aa3-d1bb-46d8-83cd-ed220cf450b5
Buoli, Massimiliano
60c3b145-3335-4e44-97df-705b561af888
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Altamura, A. Carlo
4cb41390-7275-49ec-9bef-5e517e671df4
Dell'Osso, Bernardo, Buoli, Massimiliano, Baldwin, David S. and Altamura, A. Carlo
(2010)
Serotonin norepinephrine reuptake inhibitors in anxiety disorders: a comprehensive review of their clinical efficacy.
Human Psychopharmacology: Clinical and Experimental, 25 (1), .
(doi:10.1002/hup.1074).
Abstract
Anxiety disorders are common psychiatric conditions that typically require long-term treatment. This review summarizes current knowledge of the pharmacological treatment of anxiety disorders with serotonin norepinephrine reuptake inhibitors (SNRIs) with specific emphasis on the findings of recent randomized clinical trials and relevant neurobiological investigations. It is now well established that gabaergic, noradrenergic and serotonergic systems play a critical role in the pathophysiology of anxiety disorders, abnormalities in these systems being related to structural and functional alterations in specific brain areas such as the amygdala, prefrontal cortex, locus coeruleus and hippocampus, as repeatedly shown by neuroimaging studies. SNRIs selectively inhibit norepinephrine and serotonin reuptake and have shown to be efficacious and generally well tolerated treatments in patients with anxiety disorders, with some potential clinical advantages over selective serotonin reuptake inhibitors (SSRIs), which are considered by many to represent first-line pharmacological treatments in patients with anxiety disorders. Anxiety disorders are characterized by a typically chronic course, high rates of comorbidity and frequent partial response to standard treatments, and the increasing use of SNRIs reflects currently unmet clinical need, in terms of overall response, remission rates and treatment tolerability.
This record has no associated files available for download.
More information
Published date: January 2010
Keywords:
serotonin norepinephrine reuptake inhibitors (SNRIs), anxiety disorders (ADs), selective serotonin reuptake inhibitors (SSRIs)
Identifiers
Local EPrints ID: 148115
URI: http://eprints.soton.ac.uk/id/eprint/148115
ISSN: 0885-6222
PURE UUID: d3435528-f269-442f-a763-2feae84623d4
Catalogue record
Date deposited: 27 Apr 2010 11:19
Last modified: 14 Mar 2024 02:38
Export record
Altmetrics
Contributors
Author:
Bernardo Dell'Osso
Author:
Massimiliano Buoli
Author:
A. Carlo Altamura
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics